RxDoctor Payments Data

David Cos, MD

Internal Medicine · The Woodlands, TXNPI 1265591242

Payments from drug & device makers

$17,003in general payments, 2019–2025

Across 1,175 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$903
  • AstraZeneca$878
  • Lilly USA, LLC$744
  • Amgen$736
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$16,942100%
  • Education$610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)179$2,425
Novo Nordisk126$1,609
Pfizer91$903
AstraZeneca(2 entities)43$878
Lilly USA, LLC65$744
Amgen51$736
Boehringer Ingelheim45$718
Amarin Pharma, Inc.47$647
Sanofi-aventis U.S. LLC45$573
Takeda Pharmaceuticals U.S.A., Inc.32$508
Astellas Pharma US Inc36$470
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$467
Johnson & Johnson38$455
Dexcom, Inc.27$432
GSK24$405
Bayer17$365
Tris Pharma Inc6$297
Radius Health, Inc.17$293
Biohaven Pharmaceutical Holding Company Ltd.23$285
Novartis14$245
Abbott12$227
Sunovion Pharmaceuticals Inc.22$194
Axsome Therapeutics, Inc.7$188
Biohaven Pharmaceuticals, Inc.11$183
Otsuka America Pharmaceutical, Inc.13$182
Ironwood Pharmaceuticals, Inc8$167
Eisai Inc.9$167
Biotronik Inc.1$160
Mylan Specialty L.p.8$159
Kowa Pharmaceuticals America, Inc.10$158
Antares Pharma, Inc.8$146
IBSA Pharma Inc.6$104
Shire North American Group Inc7$98
Sumitomo Pharma America, Inc.10$85
Esperion Therapeutics, Inc.5$82
Sanofi Pasteur Inc.4$76
Exact Sciences4$74
Idorsia Pharmaceuticals US Inc4$72
Merck5$68
Vertiflex, Inc.4$66
Arbor Pharmaceuticals, Inc.4$59
Optinose US, Inc.3$58
Melinta Therapeutics, LLC3$52
Edwards Lifesciences2$47
Currax Pharmaceuticals LLC3$45
Scilex Pharmaceuticals Inc.3$42
Ironshore Pharmaceuticals Inc.3$40
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$36
Corium, LLC2$36
E.r. Squibb & Sons, L.L.C.2$35
Halozyme Inc2$33
Insulet Corporation2$30
Adlon Therapeutics L.p.2$28
Metuchen Pharmaceuticals2$28
Acerus Pharmaceuticals Corporation2$25
Inspire Medical Systems, Inc.1$24
Aytu Biopharma, Inc.2$24
Jazz Pharmaceuticals Inc.1$22
Teva Pharmaceuticals USA, Inc.1$20
Clarus Therapeutics Inc.3$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,003 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,290
Medicare patients
485
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$84,929
JardianceEmpagliflozin37$43,946
EliquisApixaban32$37,756
TrulicityDulaglutide18$31,242
MounjaroTirzepatide17$26,747
FarxigaDapagliflozin Propanediol14$17,717
XareltoRivaroxaban24$17,187
GemtesaVibegron16$16,455
Tresiba Flextouch U-200Insulin Degludec16$14,924
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$12,784
MyrbetriqMirabegron14$12,680
SynthroidLevothyroxine Sodium113$9,912
VascepaIcosapent Ethyl16$9,507
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$9,157
PremarinEstrogens, Conjugated15$4,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,609$84,92953 claims
Lilly USA, LLCTrulicity, Mounjaro$744$57,98835 claims
Boehringer IngelheimJardiance$718$43,94637 claims
PfizerEliquis, Premarin$903$42,25547 claims
AstraZenecaFarxiga$878$17,71714 claims
Johnson & JohnsonXarelto$455$17,18724 claims
Sumitomo Pharma America, Inc.Gemtesa$85$16,45516 claims
Astellas Pharma US IncMyrbetriq$470$12,68014 claims
AbbVieSynthroid$2,425$9,912113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →